21/09/2026
Are you looking for a targeted therapy product for Advanced Kidney Cancer / RCC?
💊 LUCIAXI® 5 mg
Axitinib Tablets | 60 Tablets | Rx Only
LuciAXI® 5 mg contains Axitinib, a targeted tyrosine-kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer.
🎯 MAIN THERAPEUTIC USE
Advanced Renal Cell Carcinoma (RCC)
Axitinib is used in appropriate advanced RCC treatment settings, including certain combination regimens and, depending on the indication, after previous systemic therapy.
💎 PRODUCT VALUE
✔️ Specialized oncology molecule
✔️ VEGFR-targeted therapy
✔️ Established RCC treatment category
✔️ Oral tablet formulation
✔️ 5 mg strength
✔️ 60-tablet pack
🌍 For Pharmaceutical Importers, Distributors, Wholesalers & Oncology Buyers
Looking to add Axitinib to your oncology portfolio?
📩 Contact us for product availability, quotation and B2B supply information.
Gets Al Shifa Is Best Option For.
Contact Us on WhatsApp: 01575-308158
: